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Background: Dynamic susceptibility contrast (DSC)-MRI is a well-established perfusion MR imaging technique for
estimating relative cerebral blood volume (CBV) in primary brain tumors; however, tumors localized to regions with
naturally elevated perfusion, including cortical tissue and common vascular territories, make evaluation of tumor
vascularity difficult to assess. In the current study, we have constructed a large-scale radiographic atlas of CBV to
assess treatment response to bevacizumab in individual patients with recurrent glioblastoma.
Methods: Z-score normalized CBV maps were registered to stereotactic atlas space in 450 patients with brain
tumors. A CBV atlas was created by calculating the voxel-wise mean and variability in CBV. MRI and CBV maps
from 32 recurrent glioblastoma patients were then obtained prior to and following treatment with bevacizumab,
registered to and compared with the CBV atlas. The volume of tumor tissue with elevated CBV, percentage of
enhancing tumor with elevated CBV, and the mean and maximum change in normalized CBV intensity relative to
the atlas were computed.
Results: Voxel-wise comparison of individual patient CBV maps to the atlas allowed delineation of elevated tumor
perfusion from artery and normal cortical tissue. An atlas-defined hypervascular tumor blood volume greater than
2.35 cc prior to treatment, 0.14 cc after treatment, and a decrease in atlas-defined hypervascular tumor volume less
than 80% following treatment were characteristic of a shorter PFS and OS. Traditional measures of CBV were not
predictive of PFS or OS.
Conclusions: This study highlights the advantages of large-scale population maps to identify abnormal biological
tissues.
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Malignant primary brain tumors are among the most
aggressive and devastating cancers, frequently leading
to profound disabilities and death. Glioblastoma multi-
forme (GBM), the most aggressive form of malignant gli-
oma, carries a particularly poor patient prognosis [1].* Correspondence: bellingson@mednet.ucla.edu
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unless otherwise stated.Standard initial therapy for GBM consists of maximal
surgical resection followed by aggressive radiochemo-
therapy [2,3] and yields a median survival of between 12
and 15 months [2,3].
Malignant gliomas thrive by co-opting pre-existing
vasculature and inducing formation of new blood vessels
[4-6]. This finding has ushered in the use of anti-
angiogenic therapies to normalize the tumor vasculature
for the purposes of increased penetration of chemother-
apeutics or starving the tumor of nutrients. Bevacizu-
mab, a humanized monoclonal antibody for VEGF, is the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recurrent GBM. The potential alterations of anti-angiogenic
therapies on tumor vasculature has led to the interest in
surrogate biomarkers for evaluating therapeutic response
[7]. Dynamic susceptibility contrast (DSC)-MRI, a specific
perfusion magnetic resonance imaging (MRI) technique
that can be used to estimate cerebral blood volume (CBV)
or blood flow (CBF), has been shown to predict tumor
grade [8-10] and predict survival in low-grade gliomas
[11]. Preliminary results in anti-angiogenic therapy, how-
ever, have not been particularly fruitful and, at times, ap-
pear counter-intuitive [12].
A wide variability in MR scanner hardware and acqui-
sition parameters leading to variability in CBV measure-
ments are likely a significant factor contributing to the
lack of correlation observed between perfusion MRI and
response to anti-angiogenic agents. Therefore, in the
present work, we chose to utilize a population-based
CBV atlas derived from the normal tissue in 450 CBV
maps from 450 different patients collected under a var-
iety of scan protocols in order to maximize the specifi-
city for identify hypervascular tissue in GBM patients. In
this way, the variability in CBV due to different hardware
and sequence parameters are captured within the CBV
atlas, requiring a high threshold of CBV within tumor
for classification as abnormal. Using this approach, we in-
vestigated the relationship between CBV abnormalities
relative to this atlas and survival in 32 patients with recur-
rent glioblastoma treated with bevacizumab. Specifically,
we measured the volume of hypervascularity, percentage
of hypervascular tumor within areas of contrast enhance-




A total of 450 patients with DSC-MRI were retrospectively
selected from our neuro-oncology database. All patients
gave appropriate institutional review board approved in-
formed consent to have their information stored in our
database (UCLA IRB #10-000655; Reviewed by Medical
IRB Panel 2). All image acquisition and processing was
performed according to appropriate Health Insurance
Portability and Accountability Act (HIPAA) regulations.
All patients included in the atlas had brain tumors and
were not selected based on any specific histological or
treatment criteria. In particular, a total of 83 WHO II, 136
WHO III, and 231 WHO IV tumors were included, of
which 43 patients were not undergoing any systemic ther-
apy, 20 patients had undergone previous external beam
radiotherapy only, 20 patients underwent previous chemo-
therapy only, and 367 patients had previously undergone
both external beam radiation therapy and chemotherapy
at the time of DSC-MRI acquisition. No patients weretreated with anti-angiogenic therapies, immunotherapies,
or other experimental therapies at the time of perfusion
MRI. Additionally, a total of 236 patients did not have any
previous tumor progression, 163 patients had one tumor
progression, and 51 patients had two or more tumor re-
currences prior to perfusion MRI acquisition. The ration-
ale for including a wide range of patients and treatments
was to maximize the specificity for detecting hypervascu-
lar tissue within the primary tumor region in subsequent
comparisons with brain tumor patients. After DSC-MRI
data was obtained for atlas patients, regions of tumor de-
fined by T2/FLAIR hyperintensity were removed during
atlas creation to ensure the atlas consisted of only normal-
appearing brain tissue. (Of course, there is the possibility
of invading tumor beyond T2/FLAIR hyperintense re-
gions; however, these regions are not likely to contain
tumor with significant angiogenesis). The dates of acquisi-
tion of perfusion MR scans included in the atlas ranged
from July 2010 to August 2012.
Bevacizumab therapy
A total of 32 patients with recurrent GBM treated with
bevaciumab, separate from the patients used in the atlas,
were chosen from our neuro-oncology database. Patients
included in this analysis were not included in calculation
of the CBV atlas and were also selected from scans ac-
quired between October 2010 and July 2013. For each of
these patients, one DSC-MRI scan within one month
prior to treatment with bevacizumab (pre-treatment)
and within 3 months following the first dose of bevacizu-
mab (post-treatment) were used for analysis. Additionally,
all patients treated with bevacizumab at recurrence
were at least one month after completion of radiother-
apy to limit contributions of pseudoprogression. Pa-
tients were also excluded if DSC-MRI did not have full
coverage of the contrast-enhancing lesion on post-
contrast T1-weighted images.
Magnetic resonance imaging
DSC-MR images and the post-contrast T1-weighted images
were acquired using standard pulse sequences on either
1.5 T MR (Siemens Avanto, Siemens Sonata, Siemens Sym-
phony, Siemens Magnetom Vision, Siemens Healthcare;
GE Genesis, GE Signa Excite, GE Signa HDx, GE Medical
Systems; Philips Intera, Philips Medical Systems) or 3.0 T
MR (Siemens Trio, Siemens Healthcare). A 0.025 mmol/kg
pre-load dose of gadolinium contrast agent was adminis-
tered prior to DSC-MRI to diminish T1 relaxation effects
of contrast agent extravasation [10,13,14]. A 3-5 cc/sec
bolus of either gadopentetate dimeglumine (Gd-DTPA;
Magenvist, Bayer Schering Pharma, Leverkusen, Germany),
administered at a dose of 10-20 cc (0.075 mmol/kg), or
gadobenate dimeglumine (Gd-BOPTA; Multihance, Bracco
Diagnostics, Princeton, NJ), administered at a dose of
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DSC as well as the subsequent post-contrast T1-weighted
images (total of 0.01 mmol/kg). DSC-MRI scan parameters
ranged from 23-50 ms for echo times (TE), 1250-1400 ms
for repetition times (TR), 30-35 for flip angles (FA), 40-90
repetitions, 4-7 mm for slice thickness with interslice gap
from 0-1.5 mm, 6 – 20 for number of slices, and 80 × 96
to 128 × 128 for matrix sizes.
DSC-MRI data analysis
Parametric maps were calculated using the commercially
available post-processing software (IB Neuro v2.0; Im-
aging Biometrics, Elm Grove, WI) from the MR perfu-
sion images. The analysis of the DSC-MRI images
consisted of the following steps: 1) truncation of the first
five time points, at which point the MR signal will reach
its steady state; 2) conversion of the DSC-MRI time
series to a concentration-time curve based on the T2*
relaxivity of the contrast agent, using the pre-bolus sig-
nal intensity as a correction factor; 3) estimation of CBV
on a voxel-wise basis through a 120-point trapezoidal in-
tegration method, with correction for leakage [10]; and
4) standardization of the CBV grayscale values [15].
Initial affine registration
All images (450 CBVs for the atlas, along with 64 CBVs,
which consisted of 32 pre-treatment CBVs, 32 post-
treatment CBVs, and corresponding T1 post-contrast im-
ages from 32 patients, for survival analysis) for each patient
were registered to a 1.0-mm isotropic brain atlas (Montreal
Neurological Institute 152) by using a mutual information
algorithm and a 12 degrees of freedom transformation
through the Functional MR Imaging of the Brain Software
Library (http://www.fmrib.ox.ac.uk/fsl/). Adequate align-
ment was determined ensuring less than ±5 degrees rota-
tion and less than ±2.5 mm translation of the brain defined
by specific anatomic landmarks (e.g. AC-PC line, edge of
brain, alignment of ventricles, etc.). This was followed by
visual inspection by two independent raters (B.M.E., more
than 5 years of experience, and WBP, more than 10 years
of experience) to verify adequate alignment.
Regions of interest
The regions of interest (ROI) were created using custom
scripts in Analysis of Functional NeuroImages (AFNI)
software (http://afni.nimh.nih.gov/afni). The process in-
volved 1) manually defining the relative region of tumor
occurrence, 2) thresholding the post-contrast T1-weighted
images, both pre-treatment and post-treatment, in the 32
GBM patients, and 3) manually editing the resulting
masks to exclude necrotic areas. ROIs were drawn on all
slices that contained enhancing tumor. Correct segmenta-
tion was verified independently by two investigators (K.L,
B.M.E.).Definition of disease progression
Progression was defined prospectively by the treating
neuro-oncologists if subsequent scans showed an in-
crease in imaging-evaluable tumor (≥25% increase in the
sum of enhancing lesions, new enhancing lesions >1 cm2,
an unequivocal qualitative increase in nonenhancing
tumor, or an unequivocal new area of noncontrast enhan-
cing tumor). Change in steroid dosage was taken into con-
sideration while defining progression. More specifically,
patients were required to have stable or decreasing con-
trast agent dose before partial or complete response could
be determined. Additionally, patients requiring increased
dosage of steroids in order to maintain neurologic func-
tion, even in the absence of worsening on anatomical im-
ages, were considered to be stable, but required early
reevaluation. Patients who experienced significant neuro-
logic decline were also declared to have progressed at
the time of irreversible decline. Progression-free sur-
vival (PFS) was therefore defined as being the number
of days between the start of bevacizumab and declared
progression. Overall survival (OS) was defined as the
number of days between the start of bevacizumab treat-
ment to death. For all assessments that required the use
of the post-treatment scan, landmark analyses were per-
formed. Landmark survival was defined as the difference
between 1) the original PFS or OS values and 2) the num-
ber of days between the time of the post-treatment scan
and progression.
Traditional cerebral blood volume measurements
Standardized CBV maps were used for the 32 GBM pa-
tients on bevacizumab as a traditional approach to quan-
tifying CBV. Mean and maximum CBV was measured
within the tumor ROIs mentioned above. Statistical ana-
lyses were performed in the same manner as those per-
formed with atlas-defined perfusion parameters.
CBV atlas-defined perfusion parameters
The atlas was created using custom bash scripts and AFNI.
CBV data for each patient was normalized by custom
c-code and bash scripts, courtesy of the National Institutes
of Mental Health Magnetoencephallography Core Facility
(3dNormalize; NIMH MEG Core, Bethesda, MD; kurage.
nimh.nih.gov/meglab/Med/3dNormalize). Briefly, the stan-
dardized CBV maps for each patient were subtracted by
the mean CBV of the whole brain and divided by the
standard deviation of CBV throughout the brain to obtain
a resultant z-score normalized map of CBV measure-
ments. Whole brain CBV measures were obtained by first
segmenting the brain using the brain extraction tool
(BET) then calculating both the mean and standard devi-
ation of CBV throughout the entire brain mask. This
method of normalization has previously been shown to re-
duce variability in CBV measurments in the same patient
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protocols [16]. After registration to MNI space, the aver-
age z-score normalized CBV for each image voxel was cal-
culated across all 450 patients, excluding areas of tumor
as defined by T2/FLAIR hyperintense regions, leaving only
regions of relatively normal tissue for formation of the
atlas. Exclusion of these regions was chosen based on the
large number of non-enhancing, low-grade gliomas in-
cluded in the atlas as well as recent evidence from Jain
et al. [17] demonstrating that CBV within these regions
are altered in high-grade gliomas.
The same z-score normalization procedure was per-
formed on each of the individual recurrent glioblastoma
patients treated with bevacizumab. The individual z-score
normalized CBV maps were subsequently subtracted from
the CBV atlas on a voxel-by-voxel basis. Atlas-defined per-
fusion parameters included: 1) the volume of atlas-defined
elevated tissue within T1 post-contrast lesions; 2) the per-
centage of the tumor with elevated CBV; and 3) the mean
value of atlas-corrected elevated CBV tissue within the
same ROI.Figure 1 Non-responder to bevacizumab (PFS =36 days; OS =62 days).
Z-score normalized CBV. C) CBV atlas. D) Pre-treatment, atlas-defined hypervas
to therapy. E) Post-treatment, post-contrast T1-weighted image. F) Z-score no
tumor tissue showing a large residual volume of abnormal vasculature after aStatistical analysis
Patient stratification was optimized according to level of
significance (p-value) on univariate Cox proportional
hazards regression analysis with the parameter of inter-
est and either PFS or OS, using the “coxphfit” function
in the MATLAB Statistics Toolbox. The thresholds
established in this regression model were used to create
Kaplan-Meier survival curves and their subsequent log-
rank analyses. To avoid having extremely skewed groups
(e.g., 3 patients in one group versus 29 in the other), the
number of patients either above or below the cutoff was
at minimum 1/3 of the patient sample. A multivariate
Cox proportional regression model was subsequently
performed on all significant parameters according to the
log-rank analysis using MATLAB. Predictors included
age, tumor volume, and the parameter being examined,
while the observed response was either OS or PFS.
Tumor volume in the regression matched the time point
of the scan. For instance, if the parameter was based on
atlas defined pre-treatment elevated CBV volume, then
“tumor volume” was the volume of enhancing tumor inA) Pre-treatment, post-contrast T1-weighted image. B) Pre-treatment,
cular tumor tissue showing a large extent of abnormal vasculature prior
rmalized CBV. G) CBV atlas. H) Post-treatment, atlas-defined hypervascular
dministration of bevacizumab.
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ters, an ROC curve analysis was performed on one of the
following: 6-month OS, 5-month landmark OS, 3-month
PFS, or 2-month landmark PFS at the determined thresh-
old, depending on the time point at which the parameter
was measured and what clinical endpoint was used.
Results
The resulting CBV atlas is comprised of the composite,
average z-score normalized CBV values across a total of
450 patients (Figures 1C,G and 2C,G). The resulting
atlas indicates the ventricles and periventricular areas
have low values of CBV compared to the rest of the
brain. As expected, the CBV atlas also demonstrated
areas of high CBV in and adjacent to cortical tissue as
well as along the sagittal midline.
Next, we investigated the utility of the CBV atlas in de-
fining hypervascular tissue in 32 patients with recurrent
glioblastoma treated with bevacizumab. In particular, we
examined the volume of atlas-defined hypervascular tis-
sue, the percentage of enhancing tumor with elevatedFigure 2 Responder to bevaciuzumab (PFS =114 days; OS =486 days)
Z-score normalized CBV. C) CBV atlas. D) Pre-treatment, atlas-defined hyper
vasculature prior to therapy. E) Post-treatment, post-contrast T1-weighted i
hypervascular tumor tissue showing a small residual volume of abnormal vCBV, and the mean value of abnormally high CBV tissue
before and after bevacizumab to determine whether
these measurements of angiogenesis could predict PFS
and OS. In general, patients with a high volume of
hypervascular tissue prior to or after administration of
bevacizumab appeared to have a shorter PFS and OS
compared with patients exhibiting a lower volume of
hypervascular tissue. Figure 1 shows a patient that did
not respond to bevacizumab therapy, as indicated by a
short PFS of 36 days and OS of 62 days. Atlas-defined
hypervascular volume was relatively high and unchanged
for this patient, suggesting that the extent of tissue with
elevated tumor blood volume was not altered as a result
of treatment. Figure 2 shows a patient with a relatively
long PFS and OS (114 and 486 days, respectively) and a
very small volume of hypervascular tissue both before
and after bevacizumab therapy, suggesting patients with
a small volume of hypervascular tumor may have a fa-
vorable response to bevacizumab upon recurrence.
Univariate results suggested that many perfusion parame-
ters were predictive of PFS (Table 1). When examining the. A) Pre-treatment, post-contrast T1-weighted image. B) Pre-treatment,
vascular tumor tissue showing a relatively small extent of abnormal
mage. F) Z-score normalized CBV. G) CBV atlas. H) Atlas-defined
asculature after administration of bevacizumab.
Table 1 Univariate analysis for PFS and OS
PFS OS
Perfusion parameter Threshold [P-value] [P-value]
Atlas-defined perfusion parameters
Pre-Treatment
Hypervascular Volume 2.35 cc 0.0027** 0.0654
Hypervascular Volume Fraction 9% 0.8236 0.0546
Mean Z-Score Value 0.575 0.3521 0.1771
Post-Treatment
Hypervascular Volume 0.14 cc 0.0025** 0.0304*
Hypervascular Volume Fraction 8.9% 0.1320 0.0242
Mean Z-Score Value 0.5 0.1023 0.0091**
Change
Change in Volume 1 cc 0.2061 0.0563
Percentage Change in Volume 80% 0.0672 0.0483*




Mean Standardized CBV 3800 0.9704 0.0872
Post-Treatment
Mean Standardized CBV 2500 0.374 0.1499
Change
Change in Mean Standardized CBV 120 0.1209 0.3475
Max rCBV [a.u.]
Pre-Treatment
Max Standardized CBV 17000 0.7228 0.0555
Post-Treatment
Max Standardized CBV 14200 0.2022 0.0823
Change
Change in Max Standardized CBV 0 0.0316* 0.6288
* = P < 0.05, ** = P < 0.01.
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defined hypervascular volume greater than 2.35 cc had a
significantly shorter PFS compared with patients exhibiting
a lower hypervascular volume (Figure 3A, P = 0.0027).
No other pre-treatment perfusion parameters showed
significant stratification of PFS (Table 1), including trad-
itional measures of mean standardized CBV (Figure 3D,
P = 0.9704) and maximum standardized CBV (Figure 3D,
P = 0.7228). Similar to trends in pre-treatment perfu-
sion, patients with a higher post-treatment atlas-defined
hypervascular volume (>0.14 cc) had a significantly shorter
PFS (Figure 3B, P = 0.0025). Similarly, no other post-
treatment perfusion parameters showed stratification of
PFS, including traditional measures of standardized
mean CBV (Figure 3E, P = 0.3740) and maximum stan-
dardized CBV (P = 0.2022). Examination of the changein perfusion parameters after administration of bevaci-
zumab indicated a small change in atlas-defined hyper-
vascular volume trended toward a shorter PFS compared
with patients showing a large change in hypervascular vol-
ume (Figure 3C, P = 0.0672). The more traditional meas-
ure, change in maximum standardized CBV between
pre- and post-treatment scans, more successfully stratified
PFS in this instance (Figure 3F, P = 0.0316). Multivariate
Cox regression analysis indicated that pre-treatment, atlas-
defined hypervascular tumor volume was the strongest
predictor of PFS when age and contrast-enhanced tumor
volume were also considered (Table 2; P = 0.027, HR = 3.64).
Univariate analysis indicated that a large number of
perfusion parameters were predictive of OS (Table 1).
Similar to PFS, a high atlas-defined hypervascular tumor
volume prior to bevacizumab therapy trended toward
Figure 3 Relationship between perfusion parameters and progression-free survival (PFS). A) Pre-treatment, atlas-defined hypervascular
volume (Log-rank, P = 0.0027). B) Post-treatment, atlas-defined hypervascular volume (Log-rank, P = 0.0025). C) Change in atlas-defined hypervascular
volume (Log-rank, P = 0.0672). D) Pre-treatment, mean standardized CBV (black lines; Log-rank, P = 0.9704) and maximum standardized CBV
(gray lines; Log-rank, P = 0.7228). E) Post-treatment, mean standardized CBV (black lines; Log-rank, P = 0.3740) and maximum standardized CBV
(gray lines; Log-rank, P = 0.2022). F) Change in mean standardized CBV (black lines; Log-rank, P = 0.1209) and maximum standardized CBV (gray
lines; Log-rank, P = 0.0316).
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traditional mean standardized CBV did not show as
clear separation between groups (Figure 4D, P = 0.0872),
nor did maximum standardized CBV (Figure 4, P = 0.0555).
High atlas-defined hypervascular tumor volume following
bevacizumab therapy was also associated with a shorter OS
(Figure 4B, P = 0.0304), while neither mean standardized
CBV nor maximum standardized CBV was (Figure 4E,
P = 0.1499 and P = 0.0823, respectively). Lastly, a decrease
in atlas-defined hypervascular tumor volume of more than
80% was associated with a significantly longer OS com-









Age 0.98 0.02 0.94, 1.02 0.281
Pre-treatment enhancing
volume (cc)
1.01 0.01 0.98, 1.03 0.665
Pre-treatment atlas-defined
hypervasc. vol. (cc)
3.64 0.58 1.16, 11.41 0.027*
OS
Age 1.04 0.03 0.98,1.10 0.195
Post-treatment enhancing
volume (cc)
1.05 0.03 1.0,111 0.060
Post-treatment atlas-defined
hypervasc. vol. (cc)
6.15 0.73 1.46,25.87 0.013*
*= P < 0.05.(Figure 4C, P = 0.0483). Other atlas-defined perfusion pa-
rameters also showed significant associations with OS
(Table 1). Traditional measures of change in mean and
maximum standardized CBV again did not show an asso-
ciation with OS (Figure 4F, P = 0.3475 and P = 0.6288, re-
spectively). Multivariate Cox regression analysis indicated
that post-treatment, atlas-defined hypervascular tumor
volume was the strongest predictor of OS when age and
contrast-enhanced tumor volume were included as covari-
ates (Table 2; P = 0.013, HR = 6.15).
Discussion
In the current work we have effectively established a
new method of delineating regions of “abnormal” CBV
by leveraging perfusion information from a population
map based on 450 tumor patients. This atlas-based ap-
proach is favorable compared to other approaches used
in defining abnormal CBV in that it is both unbiased in
terms of the choice of CBV that defines abnormal tissue
and it also accounts for spatial heterogeneity of CBV in
the brain. In this way, tumors localized to the cortex,
where CBV is normally relatively high, would effectively
have a higher threshold for defining abnormal tissue
CBV compared with tumors localized to deep white mat-
ter regions, where CBV is relatively low. The atlas
method to quantification of abnormal vasculature allows
for better delineation of tumors that extend or infiltrate
into multiple tissue types by using spatially dependent
thresholds defined by the location on the atlas.
Figure 4 Relationship between perfusion parameters and overall survival (OS). A) Pre-treatment, atlas-defined hypervascular volume
(Log-rank, P = 0.0654). B) Post-treatment, atlas-defined hypervascular volume (Log-rank, P = 0.0304). C) Change in atlas-defined hypervascular
volume (Log-rank, P = 0.0483). D) Pre-treatment, mean standardized CBV (black lines; Log-rank, P = 0.0872) and maximum standardized CBV (gray
lines; Log-rank, P = 0.0555). E) Post-treatment, mean standardized CBV (black lines; Log-rank, P = 0.1499) and maximum standardized CBV (gray
lines; Log-rank, P = 0.0823). F) Change in mean standardized CBV (black lines; Log-rank, P = 0.3475) and maximum standardized CBV (gray lines;
Log-rank, P = 0.6288).
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hypervascular tumor as defined by comparison of indi-
vidual patients to a population-based CBV atlas is a sig-
nificant predictor of patient response and survival,
whereas traditional measures of tumor perfusion such as
mean CBV did not correlate with response or survival.
Sawlani et al. [18], in a pilot study of 16 patients, mea-
sured the change in hyperperfusion volume (ΔHPV) due
to treatment, where HPV was defined as the volume of
relative cerebral blood volume >1.25. They found that
this metric had a better correlation with progression-free
survival than the more traditional CBV metrics. A more
recent study by La Violette et al. [19] utilized a novel
approach to post-processing of DSC-MRI to show that
the volume of abnormal tumor vasculature could be
used to predict response to bevacizumab in malignant
gliomas. Together, these results appear to suggest that
the volume of abnormal vasculature, as opposed to trad-
itional perfusion MRI measures of CBV or CBF, many
be more useful for monitoring the response to anti-
angiogenic therapies.
There are a few study limitations that should be addressed.
First, variations in scan parameters in bevacizumab-treated
patients before and/or after therapy may have altered esti-
mates of traditional CBV metrics. This bias is accounted
for when using the atlas-defined perfusion parameters,
since the atlas was constructed from DSC-MRI scans
obtained under a variety of scan conditions (i.e. fieldstrengths, temporal resolution, flip angles, etc.). Another
potential limitation to the current study that should be ad-
dressed is the use of patients with brain tumors, not
healthy control subjects, to populate the atlas. In the
current study we chose to include only patients with brain
tumors for two reasons: 1) An atlas composed of only
brain tumor patients treated with a variety of therapies en-
sured that any increase in rCBV beyond these changes ob-
served during therapies would be related to growing
tumor and not due to a specific therapy. 2) Perfusion MRI
with the use of contrast is only routinely obtained in
patients with suspected or confirmed brain tumors,
stroke, or other pathologies that may influence cerebral
perfusion. Thus, building a large-scale database con-
taining hundreds of age matched (i.e. older) healthy
individuals with no suspected brain pathology is im-
practical (and some may argue could also be considered
unethical). Additionally, patients were excluded from
both construction of the atlas or assessment of anti-
angiogenic therapy if DSC-MRI data had less than 6
slices, since this increased the difficulty of aligning it in
standardized space and, in the case of treatment evalu-
ation, rarely allowed for full coverage of the tumor.
Conclusion
In the current study we have constructed a large-scale
population image map of CBV from DSC-MRI data in
450 patients, then used this atlas to compare individual
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extent of abnormal tumor vasculature. Results suggest
atlas-defined hypervascular tumor volumes predict both
response and survival in recurrent glioblastoma patients
treated with bavacizumab. This study highlights the im-
portance of using large-scale population image maps to
identify abnormal biological tissues.
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